BioSpace News Archive

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that Health Canada has issued the Company a “No Objection Letter” to proceed with the Company’s trial using XPro1595 to treat mild Alzheimer’s Disease (AD) in Canada.

Persephone Biosciences Inc., a synthetic biology company reimagining patient health through the development of microbiome-based medicines, today announced that it has enrolled the last subject in its My Baby Biome™ observational study to determine specific biomarkers that are associated with a healthy infant gut.

Co-Diagnostics, Inc. announced that it will be hosting a booth this week at the MEDICA 2022 trade fair in Düsseldorf, Germany from 15-17 November.

Panavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Thursday, November 17, 2022 at 11:45 AM ET at the Pharma Partnering US Summit 2022 being held in Boston, MA.

RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO).

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial results for the third quarter ended September 30, 2022 and provided an operational update.

A groundbreaking discovery by a Medical College of Wisconsin (MCW) microbiologist and partnership with one of its trustees has led to the founding of Rose Biosciences.

The global peptide synthesis market size was USD 315 Million in 2020 and is expected to register a CAGR of 6.4% during the forecast period.

The microcarrier market size was USD 1.4 Billion in 2020 and is expected to register a CAGR of 10.5% during the forecast period.

The global glycomics/glycobiology market size was USD 1.0 Billion in 2020 and is expected to register a CAGR of 14.1% during the forecast period.